Analysis of TCR repertoire for esophageal cancer and rectal cancer after neoadjuvant chemoradiation therapy

Analysis of TCR repertoire for esophageal cancer and rectal cancer after neoadjuvant chemoradiation therapy - Analysis of TCR repertoire for esophageal cancer and rectal cancer after neoadjuvant chemoradiation therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040551

Enrollment

1000

Registered

2020-05-27

Start date

2020-05-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer and rectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with esophageal cancer or rectal cancer for standard neoadjuvant chemoradiation

Exclusion criteria

Exclusion criteria: patients who do not give written informed consents

Design outcomes

Primary

Measure	Time frame
TCR repertoire, SNPs as well as biological factors relating to immune response for tumors	—

Countries

Japan

Contacts

Public ContactTakahiro Mori

National Hospital Organization National Sagamihara Hospital Department of Clinical Oncology

westendc7m@gmail.com+81-42-742-8311

Outcome results